Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Anesthesiology
2009 Aug 01;1112:240-9. doi: 10.1097/ALN.0b013e3181ae63d1.
Show Gene links
Show Anatomy links
Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression.
Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE.
???displayArticle.abstract???
BACKGROUND: Etomidate is a rapidly acting sedative-hypnotic that provides hemodynamic stability. It causes prolonged suppression of adrenocortical steroid synthesis; therefore, its clinical utility and safety are limited. The authors describe the results of studies to define the pharmacology of (R)-3-methoxy-3-oxopropyl1-(1-phenylethyl)-1H-imidazole-5-carboxylate (MOC-etomidate), the first etomidate analogue designed to be susceptible to ultra-rapid metabolism.
METHODS: The gamma-aminobutyric acid type A receptor activities of MOC-etomidate and etomidate were compared by using electrophysiological techniques in human alpha1beta2gamma2l receptors. MOC-etomidate's hypnotic concentration was determined in tadpoles by using a loss of righting reflex assay. Its in vitro metabolic half-life was measured in human liver S9 fraction, and the resulting metabolite was provisionally identified by using high-performance liquid chromatography/mass spectrometry techniques. The hypnotic and hemodynamic actions of MOC-etomidate, etomidate, and propofol were defined in rats. The abilities of MOC-etomidate and etomidate to inhibit corticosterone production were assessed in rats.
RESULTS: MOC-etomidate potently enhanced gamma-aminobutyric acid type A receptor function and produced loss of righting reflex in tadpoles. Metabolism in human liver S9 fraction was first-order, with an in vitro half-life of 4.4 min versus more than 40 min for etomidate. MOC-etomidate's only detectable metabolite was a carboxylic acid. In rats, MOC-etomidate produced rapid loss of righting reflex that was extremely brief and caused minimal hemodynamic changes. Unlike etomidate, MOC-etomidate produced no adrenocortical suppression 30 min after administration.
CONCLUSIONS: MOC-etomidate is an etomidate analogue that retains etomidate's important favorable pharmacological properties. However, it is rapidly metabolized, ultra-short-acting, and does not produce prolonged adrenocortical suppression after bolus administration.
Absalom,
Adrenocortical function in critically ill patients 24 h after a single dose of etomidate.
1999, Pubmed
Absalom,
Adrenocortical function in critically ill patients 24 h after a single dose of etomidate.
1999,
Pubmed Belelli,
The in vitro and in vivo enantioselectivity of etomidate implicates the GABAA receptor in general anaesthesia.
2003,
Pubmed
,
Xenbase Bentley,
Age and fentanyl pharmacokinetics.
1982,
Pubmed Bodor,
Soft drug design: general principles and recent applications.
2000,
Pubmed Cole,
Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies.
2000,
Pubmed Como,
Oral azole drugs as systemic antifungal therapy.
1994,
Pubmed Cotton,
Increased risk of adrenal insufficiency following etomidate exposure in critically injured patients.
2008,
Pubmed de Jong,
Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation.
1984,
Pubmed den Brinker,
One single dose of etomidate negatively influences adrenocortical performance for at least 24h in children with meningococcal sepsis.
2008,
Pubmed den Brinker,
Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality.
2005,
Pubmed de Ruiter,
Pharmacokinetics of etomidate in surgical patients.
1981,
Pubmed Ebert,
Sympathetic responses to induction of anesthesia in humans with propofol or etomidate.
1992,
Pubmed Egan,
Is anesthesiology going soft?: trends in fragile pharmacology.
2009,
Pubmed Egan,
The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers.
1993,
Pubmed Egan,
Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.
1996,
Pubmed Fish,
Contrasting effects of etomidate and propylene glycol upon enflurane metabolism and adrenal steroidogenesis in Fischer 344 rats.
1988,
Pubmed Gooding,
Effect of etomidate on the cardiovascular system.
1977,
Pubmed Gooding,
Cardiovascular and pulmonary responses following etomidate induction of anesthesia in patients with demonstrated cardiac disease.
1979,
Pubmed Haidar,
Evaluating a possible pharmacokinetic interaction between remifentanil and esmolol in the rat.
1997,
Pubmed Hebron,
Pharmacokinetics of etomidate associated with prolonged i.v. infusion.
1983,
Pubmed Hildreth,
Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study.
2008,
Pubmed Husain,
Synthesis of trifluoromethylaryl diazirine and benzophenone derivatives of etomidate that are potent general anesthetics and effective photolabels for probing sites on ligand-gated ion channels.
2006,
Pubmed
,
Xenbase Husain,
2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
2003,
Pubmed
,
Xenbase Johnson,
Experimentally-induced hyperthyroidism is associated with activation of the rat hypothalamic-pituitary-adrenal axis.
2005,
Pubmed Jurd,
General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit.
2003,
Pubmed Ledingham,
Influence of sedation on mortality in critically ill multiple trauma patients.
1983,
Pubmed Liao,
R (+) etomidate and the photoactivable R (+) azietomidate have comparable anesthetic activity in wild-type mice and comparably decreased activity in mice with a N265M point mutation in the gamma-aminobutyric acid receptor beta3 subunit.
2005,
Pubmed Lipiner-Friedman,
Adrenal function in sepsis: the retrospective Corticus cohort study.
2007,
Pubmed Lundy,
Acute adrenal insufficiency after a single dose of etomidate.
2007,
Pubmed Malerba,
Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation.
2005,
Pubmed McCollum,
Comparison of induction characteristics of four intravenous anaesthetic agents.
1986,
Pubmed Pont,
Ketoconazole blocks adrenal steroid synthesis.
1982,
Pubmed Roumen,
Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics.
2007,
Pubmed Rüsch,
Gating allosterism at a single class of etomidate sites on alpha1beta2gamma2L GABA A receptors accounts for both direct activation and agonist modulation.
2004,
Pubmed
,
Xenbase Schleimer,
Pharmacokinetics of fentanyl as determined by radioimmunoassay.
1978,
Pubmed Sprung,
Hydrocortisone therapy for patients with septic shock.
2008,
Pubmed Sum,
Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite.
1983,
Pubmed Vinclair,
Duration of adrenal inhibition following a single dose of etomidate in critically ill patients.
2008,
Pubmed Wagner,
Inhibition of adrenal steroidogenesis by the anesthetic etomidate.
1984,
Pubmed Wagner,
Etomidate inhibits adrenocortical function in surgical patients.
1984,
Pubmed Watt,
Mortality amongst multiple trauma patients admitted to an intensive therapy unit.
1984,
Pubmed Waud,
On biological assays involving quantal responses.
1972,
Pubmed Westmoreland,
Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery.
1993,
Pubmed Wiest,
Pharmacokinetics of esmolol in children.
1991,
Pubmed Williams,
Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.
1986,
Pubmed Zolle,
New selective inhibitors of steroid 11beta-hydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues.
2008,
Pubmed
